Evidence map›Paper›PMID 30519133›Full record

ArticleLung Cancer (Auckland, N.Z.)2018

Dramatic response to alectinib in a lung cancer patient with a novel

Viola W Zhu, Alexa B Schrock, Thangavijayan Bosemani, Bryan S Benn, Siraj M Ali, Sai-Hong Ignatius Ou

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Lung Cancer (Auckland, N.Z.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Catalog of 5' Fusion Partners inJTO clinical and research reports · 2020
    Review
  6. Coexisting ofOncoTargets and therapy · 2020
    Article
  7. Emerging therapies for non-small cell lung cancer.Journal of hematology & oncology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Viola W ZhuChao Family Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine School of Medicine, Orange, CA, USA, zhuvw@uci.edu.
Alexa B SchrockClinical Development, Foundation Medicine, Inc., Cambridge, MA, USA.
Thangavijayan BosemaniDepartment of Radiological Sciences, University of California, Irvine School of Medicine, Orange, CA, USA.
Bryan S BennDivision of Pulmonary Diseases and Critical Care Medicine, Department of Medicine, University of California, Irvine School of Medicine, Orange, CA, USA.
Siraj M AliClinical Development, Foundation Medicine, Inc., Cambridge, MA, USA.
Sai-Hong Ignatius OuChao Family Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine School of Medicine, Orange, CA, USA, zhuvw@uci.edu.
University of California, Irvine · USFoundation Medicine (United States)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

crizotinibfusionlorlatinibresistanceT1151VKORC1L1

Identifiers

PMID30519133
PMCPMC6234987
OpenAlexW2900238168

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.